Literature DB >> 14633707

Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance.

Theresa M Grana1, Carolyn I Sartor, Adrienne D Cox.   

Abstract

Oncogenic forms of the small GTPase Ras increase the resistance of cells to killing by ionizing radiation (IR). Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by phosphatidylinositol 3'-kinase (PI3-K) and Raf. Nevertheless, PI3-K and Raf together are not sufficient to reconstitute all of the resistance conferred by Ras, indicating that other effectors must also contribute. We show here that Ras-driven autocrine signaling through the epidermal growth factor receptor (EGFR) also contributes to radioresistance in Ras-transformed cells. Conditioned media (CM) collected from RIE-1 rat intestinal epithelial cells expressing oncogenic Ras increased the survival of irradiated cells. Ras-CM contains elevated levels of the EGFR ligand transforming growth factor alpha (TGF-alpha). Both Ras-CM and TGF-alpha stimulated EGFR phosphorylation, and exogenous TGF-alpha mimicked the effects of Ras-CM to increase radioresistance. Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells. Ras-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016. Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer. The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633707

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.

Authors:  Aimee K Bence; Eric B Anderson; Maqbool A Halepota; Michael A Doukas; Phillip A DeSimone; George A Davis; Deborah A Smith; Kevin M Koch; Andrew G Stead; Steve Mangum; Carolyn J Bowen; Neil L Spector; Showchien Hsieh; Val R Adams
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

2.  ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.

Authors:  Zana K Ahmad; Carrie M Brown; Roberto A Cueva; Allen F Ryan; Joni K Doherty
Journal:  Otol Neurotol       Date:  2011-07       Impact factor: 2.311

3.  The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation.

Authors:  Ning Yin; Adrienne Lepp; Yongsheng Ji; Matthew Mortensen; Songwang Hou; Xiao-Mei Qi; Charles R Myers; Guan Chen
Journal:  J Biol Chem       Date:  2017-07-24       Impact factor: 5.157

4.  Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.

Authors:  Ambrose R Kidd; Jared L Snider; Timothy D Martin; Sarah F Graboski; Channing J Der; Adrienne D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-07       Impact factor: 7.038

5.  Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

Authors:  Maria J Sambade; Eldon C Peters; Nancy E Thomas; William K Kaufmann; Randall J Kimple; Janiel M Shields
Journal:  Radiother Oncol       Date:  2011-02-04       Impact factor: 6.280

6.  Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.

Authors:  Maria J Sambade; J Terese Camp; Randall J Kimple; Carolyn I Sartor; Janiel M Shields
Journal:  Radiother Oncol       Date:  2009-10-23       Impact factor: 6.280

7.  Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

Authors:  Randall J Kimple; Angelina V Vaseva; Adrienne D Cox; Kathryn M Baerman; Benjamin F Calvo; Joel E Tepper; Janiel M Shields; Carolyn I Sartor
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

8.  Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition.

Authors:  Ariella B Hanker; Kevin D Healy; Jean Nichols; Channing J Der
Journal:  J Mol Signal       Date:  2009-08-16

9.  Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

Authors:  Keith A Cengel; K Rahn Voong; Sanjay Chandrasekaran; Laurence Maggiorella; Thomas B Brunner; Eric Stanbridge; Gary D Kao; W Gillies McKenna; Eric J Bernhard
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

10.  MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.

Authors:  Eun Joo Chung; Mary Ellen Urick; Naamit Kurshan; William Shield; Hiroaki Asano; Paul D Smith; Bradley S Scroggins; Jeffrey Burkeen; Deborah E Citrin
Journal:  Int J Oncol       Date:  2013-04-10       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.